ATE128032T1 - Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten. - Google Patents

Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.

Info

Publication number
ATE128032T1
ATE128032T1 AT90307502T AT90307502T ATE128032T1 AT E128032 T1 ATE128032 T1 AT E128032T1 AT 90307502 T AT90307502 T AT 90307502T AT 90307502 T AT90307502 T AT 90307502T AT E128032 T1 ATE128032 T1 AT E128032T1
Authority
AT
Austria
Prior art keywords
obesity
treatment
preparation
essential hypertension
related diseases
Prior art date
Application number
AT90307502T
Other languages
English (en)
Inventor
Garth J S Cooper
Brendan Leighton
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE128032T1 publication Critical patent/ATE128032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AT90307502T 1989-07-10 1990-07-10 Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten. ATE128032T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37765289A 1989-07-10 1989-07-10

Publications (1)

Publication Number Publication Date
ATE128032T1 true ATE128032T1 (de) 1995-10-15

Family

ID=23490003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90307502T ATE128032T1 (de) 1989-07-10 1990-07-10 Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.

Country Status (14)

Country Link
EP (1) EP0408294B1 (de)
JP (1) JPH04500688A (de)
AT (1) ATE128032T1 (de)
AU (1) AU620727B2 (de)
CA (1) CA2020786A1 (de)
DE (1) DE69022501T2 (de)
DK (1) DK0408294T3 (de)
ES (1) ES2080802T3 (de)
FI (1) FI911179A0 (de)
GR (1) GR3018442T3 (de)
IE (1) IE71195B1 (de)
NO (1) NO910901L (de)
NZ (1) NZ234428A (de)
WO (1) WO1991000737A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
WO1992020367A1 (en) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
DE69333683T2 (de) * 1992-05-15 2005-10-27 Amylin Pharmaceuticals, Inc., San Diego Antikörper-testbesteck zur bestimmung von amylin
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
WO1996003993A2 (en) * 1994-08-05 1996-02-15 The Rockefeller University Modulation of thymocyte and t cell functional activity
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
CN1296384C (zh) * 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 具有preptin功能的肽
DK1957106T4 (da) 2005-11-14 2019-10-28 Teva Pharmaceuticals Int Gmbh Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
US8623366B2 (en) 2009-08-28 2014-01-07 Labrys Biologics, Inc. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN102666579A (zh) * 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
SG11201510618YA (en) * 2013-07-03 2016-03-30 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
KR20220130822A (ko) 2014-03-21 2022-09-27 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3515937A1 (de) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Behandlung von refraktärer migräne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052583T3 (es) * 1986-12-04 1994-07-16 Asahi Chemical Ind Derivados de peptidos relacionados con el gel calcitonina.
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
WO1989006135A1 (en) * 1988-01-11 1989-07-13 Amylin Corporation Treatment of type 2 diabetes mellitus

Also Published As

Publication number Publication date
ES2080802T3 (es) 1996-02-16
JPH04500688A (ja) 1992-02-06
WO1991000737A1 (en) 1991-01-24
DK0408294T3 (da) 1996-01-15
NO910901L (no) 1991-04-25
EP0408294A2 (de) 1991-01-16
DE69022501D1 (de) 1995-10-26
EP0408294B1 (de) 1995-09-20
AU620727B2 (en) 1992-02-20
NO910901D0 (no) 1991-03-07
IE902514A1 (en) 1991-02-13
AU5953790A (en) 1991-02-06
FI911179A0 (fi) 1991-03-08
DE69022501T2 (de) 1996-02-01
GR3018442T3 (en) 1996-03-31
CA2020786A1 (en) 1991-01-11
EP0408294A3 (en) 1991-12-18
NZ234428A (en) 1997-08-22
IE71195B1 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
ATE128032T1 (de) Verwendung eines amylinantagonisten zur herstellung eines artzneimittels zur behandlung von fettsucht und essentieller hypertonie und damit zusammenhängenden krankheiten.
ATE107508T1 (de) Verwendung von nalmefen oder naltrexon bei der behandlung von autoimmunerkrankungen.
ATE75407T1 (de) Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker.
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
BR8707631A (pt) Materiais e dispositivos cirurgicos
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
FR2656214B1 (fr) Cadre dynamique d'osteosynthese du rachis.
DE3873327D1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
IT9041529A0 (it) Dispositivo per la correzione chirurgica dell'ametropia
DE69805305T2 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE59003534D1 (de) Verfahren zur Herstellung von Triethylendiamin und Piperazin.
DE69209140D1 (de) Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69011465D1 (de) Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten.
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69021557D1 (de) Verwendung von derivaten von 9,10-dihydrophenanthren zur herstellung eines antitumoralen medikamentes und neuen derivaten daraus.
DE69313534T2 (de) Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time